The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Dana-Farber establishes Lubin Family Foundation Scholar Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Richard K. Lubin Family Foundation will provide a grant to establish the Lubin Family Foundation Scholar Awards at Dana-Farber Cancer Institute.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
In Brief

Christian Hinrichs, of Rutgers Cancer Institute & RWJBarnabas Health, receives V Foundation for Cancer Research award

Christian Hinrichs, co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence and chief of the Section of Cancer Immunotherapy, RWJBarnabas Health, has been awarded a four-year, $800,000 translational research grant from the V Foundation for Cancer Research to develop next-generation immunotherapies for cancers caused by human papillomavirus. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account